Neurelis was founded to license, develop, and commercialize product candidates for the broader central nervous system (CNS), including epilepsy and psychiatry. Our emphasis is on highly differentiated therapies that empower patients, care partners, and healthcare providers. The benefits of our unique platform technology allow us to form strategic partnerships to address significant unmet needs in other therapeutic areas as well.
Licensed Intravail® absorption enhancement technology from Aegis Therapeutics
Active ingredient formulated with vitamin E and Intravail® technology to create lead investigational product candidate
Pre-investigational New Drug (IND) meeting with FDA for lead investigational product candidate
Aligned with the FDA to initiate studies for pre-clinical and clinical safety programs for lead investigational product candidate
Lead investigational product candidate granted fast track designation by FDA
Neurelis acquires Aegis Therapeutics
Initiated pre-clinical activities for second and third investigational product candidates